文献速递慢性肾脏病遗传性与小管间质肾病

常染色体显性多囊肾病作为时间动态疾病:对生物标志物、试验设计与治疗靶向的启示

ADPKD as a Temporally Dynamic Disease: Implications for Biomarkers, Trial Design, and Therapeutic Targeting.
PubMed 文献 · Kidney Int Rep · 2026-09-26

本文综述提出常染色体显性多囊肾病(ADPKD)应被视为时间动态疾病,而非仅结构进展性疾病。早期以囊性、增殖和代谢活动及炎症为主,中期炎症与损伤修复突出,晚期纤维化和功能实质丧失更重要。这些过程重叠且个体差异大,需以动态生物学标志物补充结构指标并优化试验设计与治疗靶向。

要点

  • ADPKD的生物学过程随病程动态变化,早期炎症与代谢活跃,晚期纤维化主导。
  • 总肾脏体积用于风险分层和试验设计需结合反映动态生物学的标志物。
  • 治疗靶点和终点应与研究人群中驱动进展的关键过程相匹配。

核心结论

  • ADPKD应被视为时间动态疾病,其结构、功能与生物学关系随病程变化,需动态生物标志物补充结构指标并指导试验设计与靶向治疗。

研究设计与样本

  • 综述,基于纵向人类研究和实验模型,探讨ADPKD作为时间动态疾病对生物标志物、临床试验设计和治疗靶向的影响。

主要发现

  • 早期疾病以囊性、增殖和代谢活动突出及早期炎症反应为特征。
  • 中期炎症和损伤修复过程日益显著,晚期随肾功能下降纤维化和功能性实质丧失作用更大。
  • 这些过程相互重叠而非离散分期,其时序和相对贡献可能因人而异。

临床怎么用

  • 临床应动态评估ADPKD生物学过程,结构指标需结合反映演变生物学的标志物。
  • 试验设计应前瞻性识别生物学转变,并使治疗靶点和终点与研究人群的进展驱动过程对齐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) has traditionally been conceptualized as a structurally progressive disease, with cyst growth driving loss of kidney function. This view has led to the widespread use of total kidney volume for risk stratification and clinical trial design. However, longitudinal human studies and experimental models indicate that the relationship between structure, function, and underlying biology changes over the disease course. Earlier disease is characterized by prominent cystic, proliferative, and metabolic activity together with early inflammatory responses; inflammatory and injury-repair processes become increasingly prominent during intermediate disease, whereas fibrosis and loss of functional parenchyma assume a greater role later as kidney function declines. These processes overlap rather than define discrete stages, and their timing and relative contributions likely vary among individuals. This review proposes that ADPKD be considered as a temporally dynamic disease and examines the implications of this framework for biomarker development, clinical trial design, and therapeutic targeting. Such a framework emphasizes the need to complement structural measures with biomarkers of evolving biology, to identify biological transitions prospectively, and to align therapeutic targets and end points with the processes contributing meaningfully to progression in the population being studied.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Irazabal MV. ADPKD as a Temporally Dynamic Disease: Implications for Biomarkers, Trial Design, and Therapeutic Targeting. Kidney Int Rep. 2026. PMID: 42935907. doi:10.1016/j.ekir.2026.107113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。